Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative Imaging of Pulmonary Nodules by OTL38
NCT02602119Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- May 2015
- Primary completion
- May 2022
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pafolacianine in lung cancer and pleural mesothelioma, sponsored by University of Pennsylvania. Primary endpoints: Sensitivity of OTL38 in identifying lung nodules at 5 years and Microscopic examination and immunohistochemistry of tumor at 5 years. Started May 2015; status: completed.
02
Drugs
pafolacianine
03
Conditions
lung cancerpleural mesothelioma
Beyond the preview
Go deeper on NCT02602119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02602119.